Lilly's tirzepatide shows additional 21.1% weight loss

US pharma major Eli Lilly (NYSE: LLY) has released detailed results from the Phase III SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes, were published in  Nature Medicine and simultaneously presented at ObesityWeek 2023.

Dubbed the “King Kong” of obesity drugs by US expert Dr Julio Rosenstcok, tirzepatide met both co-primary endpoints for the efficacy estimand and treatment-regimen estimand, demonstrating superiority to placebo during the 72-week double-blind treatment period.

SURMOUNT-3 evaluated the efficacy and safety of tirzepatide compared to placebo for 72 weeks after a 12-week intensive lifestyle intervention lead-in period that included a low-calorie diet, exercise and frequent counseling sessions. The trial randomized adults with obesity or overweight who had at least 5% body weight reduction by the end of the 12-week lead-in period to placebo or tirzepatide. At study entry, the mean body weight was 241.4lb. (109.5kg). At the end of the 12-week lead-in period, participants achieved 6.9% (7.6 kg or 16.8 lb.) mean weight loss.